AnaptysBio (ANAB) shares were down almost 22% in recent Wednesday trading after Eli Lilly (LLY) said it is removing arthritis drug peresolimab from its pipeline.
AnaptysBio is developing rosnilimab, an arthritis treatment that is similar to peresolimab, according to media reports.
AnaptysBio previously said on Aug. 5 in its Q2 earnings release that top-line results are expected in Q1 2025 for a phase 2b trial to treat rheumatoid arthritis with rosnilimab.
Price: 24.17, Change: -6.64, Percent Change: -21.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.